Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Cut to $71.00 by Analysts at Scotiabank

Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) had its price objective reduced by Scotiabank from $74.00 to $71.00 in a research note published on Friday morning, Marketbeat reports. They currently have a sector outperform rating on the biopharmaceutical company's stock.

Several other analysts have also commented on AGIO. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 1st. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Agios Pharmaceuticals Trading Down 0.1 %

Shares of AGIO stock traded down $0.02 on Friday, reaching $28.31. 216,890 shares of the company's stock were exchanged, compared to its average volume of 698,251. The stock has a market capitalization of $1.64 billion, a PE ratio of 2.51 and a beta of 0.77. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58. The company's fifty day simple moving average is $29.60 and its 200 day simple moving average is $37.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. As a group, sell-side analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This represents a 4.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Summit Investment Advisors Inc. grew its stake in Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after buying an additional 394 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Agios Pharmaceuticals by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 582 shares during the period. KBC Group NV grew its position in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Agios Pharmaceuticals by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after acquiring an additional 708 shares in the last quarter. Finally, Atria Investments Inc grew its position in Agios Pharmaceuticals by 6.9% during the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.